{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:40Z","timestamp":1760122600216},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","progcardvascdis.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.pcad.2016.06.003","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T05:21:42Z","timestamp":1467696102000},"page":"71-77","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Group 2 PH: Medical Therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"Marco","family":"Guazzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Labate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2016.06.003_bb0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.06.003_bb0010","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2016.03.007","article-title":"Right ventricular contractile reserve and pulmonary circulation uncoupling during exercise challenge in heart failure: pathophysiology and clinical phenotypes","author":"Guazzi","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ejhf.478","article-title":"Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology","volume":"18","author":"Harjola","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0025","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.cjca.2014.10.012","article-title":"Pathophysiology and clinical relevance of pulmonary remodelling in pulmonary hypertension due to left heart diseases","volume":"31","author":"Dupuis","year":"2015","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0030","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1161\/CIRCULATIONAHA.108.838698","article-title":"Age-associated increases in pulmonary artery systolic pressure in the general population","volume":"119","author":"Lam","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0035","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0040","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1161\/CIRCHEARTFAILURE.113.000823","article-title":"Pulmonary hypertension in heart failure preserved ejection fraction: prevalence, pathophysiology, and clinical perspectives","volume":"7","author":"Guazzi","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0045","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","article-title":"Pulmonary hypertension due to left heart disease","volume":"126","author":"Guazzi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/eurjhf\/hfp171","article-title":"Caveat medicus! Pulmonary hypertension in the elderly: a word of caution","volume":"12","author":"Boilson","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0055","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study","volume":"4","author":"Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0065","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"Cody","year":"1992","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0070","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0075","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(97)00296-9","article-title":"Comparison of the effects of selective endothelin eta and etb receptor antagonists in congestive heart failure","volume":"30","author":"Wada","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0080","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0085","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0167-5273(02)00182-1","article-title":"Do results of the enable (endothelin antagonist bosentan for lowering cardiac events in heart failure) study spell the end for non-selective endothelin antagonism in heart failure?","volume":"85","author":"Kalra","year":"2002","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0090","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the Endothelina Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.06.003_bb0100","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the veritas randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.06.003_bb0115","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure Et(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/0002-9149(82)90183-7","article-title":"Prostacyclin therapy in patients with congestive heart failure","volume":"50","author":"Yui","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0125","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.ijcard.2008.12.173","article-title":"Benefit of prostaglandin infusion in severe heart failure: preliminary clinical experience of repetitive administration","volume":"146","author":"Serra","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0130","doi-asserted-by":"crossref","first-page":"34A","DOI":"10.1016\/S0002-9149(99)80381-6","article-title":"Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group","volume":"75","author":"Sueta","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0002-8703(97)70105-4","article-title":"A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST)","volume":"134","author":"Califf","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.pcad.2016.06.003_bb0140","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0003-4975(97)01307-6","article-title":"Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension","volume":"65","author":"Argenziano","year":"1998","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.pcad.2016.06.003_bb0145","first-page":"436","article-title":"Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside","volume":"14","author":"Kieler-Jensen","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2016.06.003_bb0150","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/01.CIR.95.9.2250","article-title":"Influence of inhaled nitric oxide on systemic flow and ventricular filling pressure in patients receiving mechanical circulatory assistance","volume":"95","author":"Hare","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0155","first-page":"366","article-title":"Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance","volume":"13","author":"Kieler-Jensen","year":"1994","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2016.06.003_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0002-9149(94)90496-0","article-title":"Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure","volume":"74","author":"Bocchi","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0165","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(95)92681-X","article-title":"Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide","volume":"346","author":"Miller","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.pcad.2016.06.003_bb0170","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/sj.bjp.0704984","article-title":"Increased expression of the CGMP-inhibited CAMP-specific (PDE3) and CGMP binding CGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension","volume":"137","author":"Murray","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0175","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jacc.2009.05.021","article-title":"Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil","volume":"54","author":"Melenovsky","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0180","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ejheart.2003.11.015","article-title":"Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation","volume":"6","author":"Angel Gomez-Sanchez","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0185","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.amjcard.2004.07.157","article-title":"Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure","volume":"94","author":"Alaeddini","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0190","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.127.5.1647","article-title":"Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide","volume":"127","author":"Lepore","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2016.06.003_bb0195","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0200","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ejheart.2007.01.008","article-title":"Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation","volume":"9","author":"Jabbour","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0205","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/CIRCHEARTFAILURE.108.785501","article-title":"Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone","volume":"1","author":"Lewis","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cardfail.2007.11.006","article-title":"Effects of 5\u2032-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial","volume":"14","author":"Behling","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1161\/CIRCHEARTFAILURE.108.796789","article-title":"PDE5A inhibitor treatment of persistent pulmonary hypertension after mechanical circulatory support","volume":"1","author":"Tedford","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0220","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0225","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1161\/CIRCULATIONAHA.111.024141","article-title":"Exercise oscillatory ventilation in systolic heart failure: an indicator of impaired hemodynamic response to exercise","volume":"124","author":"Murphy","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0230","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.healun.2012.09.009","article-title":"Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation","volume":"31","author":"Pons","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.pcad.2016.06.003_bb0235","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/eurjhf\/hfr147","article-title":"Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study","volume":"14","author":"Guazzi","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0240","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ijcard.2011.10.064","article-title":"Therapeutic potential of sildenafil in patients with heart failure and reactive pulmonary hypertension","volume":"154","author":"Dumitrescu","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0245","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijcard.2012.09.074","article-title":"The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case\u2013control study","volume":"168","author":"Reichenbach","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0250","doi-asserted-by":"crossref","first-page":"325","DOI":"10.12659\/AOT.890657","article-title":"Sustained improvement of clinical status and pulmonary hypertension in patients with severe heart failure treated with sildenafil","volume":"19","author":"Urbanowicz","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.pcad.2016.06.003_bb0255","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pcad.2016.06.003_bb0260","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1161\/CIRCHEARTFAILURE.108.802116","article-title":"Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure","volume":"1","author":"Guazzi","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0265","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1016\/j.jacc.2004.09.041","article-title":"The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure","volume":"44","author":"Guazzi","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0270","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0275","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2016.06.003_bb0280","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cardfail.2008.09.005","article-title":"Combined use of pde5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure","volume":"15","author":"Stehlik","year":"2009","journal-title":"J Card Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0285","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pcad.2016.06.003_bb0290","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002729","volume":"9","author":"Hussain","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pcad.2016.06.003_bb0295","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1161\/CIRCULATIONAHA.111.081125","article-title":"Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis","volume":"125","author":"Lindman","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0300","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.14-0106","article-title":"Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study","volume":"146","author":"Bonderman","year":"2014","journal-title":"Chest"},{"key":"10.1016\/j.pcad.2016.06.003_bb0305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1161\/CIRCULATIONAHA.114.014149","article-title":"Harnessing the nitrate-nitrite-nitric oxide pathway for therapy of heart failure with preserved ejection fraction","volume":"131","author":"Vanderpool","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0310","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1161\/CIRCULATIONAHA.114.012957","article-title":"Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction","volume":"131","author":"Zamani","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2016.06.003_bb0315","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jacc.2015.07.067","article-title":"Sodium nitrite improves exercise hemodynamics and ventricular performance in heart failure with preserved ejection fraction","volume":"66","author":"Borlaug","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062016300500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T14:30:44Z","timestamp":1536589844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062016300500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0033062016300500"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2016.06.003","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Group 2 PH: Medical Therapy","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2016.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}